Merck Hit With Complete Response Letter on Potential Sarcoma Drug
The FDA has handed Merck a complete response letter on Taltorvic, a potential maintenance treatment for metastatic soft-tissue and bone sarcomas, calling for additional clinical trials to assess safety and efficacy.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.